公司公告汇总 关于公司股份回购进展的公告上海悦心健康集团股份有限公司（证券代码：002162，证券简称：悦心健 康）分别于2025年2月26日、2025年3月25日召开了第八届董事会第十三次会议、2024年度股东大会，审 议通过了《关于公司回购股份方案的议案》，同意公司使用自有资金或自筹资金以集中竞价交易方式回 购公司部分已发行的人民币普通股（A股）股票，回购股份将全部用于注销并减少公司注册资本。本次 回购总金额不低于人民币600万元（含）且不超过人民币1,000万元（含），回购价格为不超过人民币5 元/股（含）。按回购价格上限5元/股测算，预计回购股份的数量区间约为120万股至200万股，占公司 目前总股本的比例区间约为0.13%至0.22%，具体回购数量以回购期限届满时实际回购的股份数量为 准。回购股份的期限自股东大会审议通过回购股份方案之日起不超过12个月。截至2025年3月31日，公 司暂未实施股份回购。公司后续将根据市场情况在回购期限内继续实施本次回购计划，并根据相关法 律、法规和规范性文件的规定履行信息披露义务。特此公告。上海悦心健康集团股份有限公司董事会二 ○二五年四月二日 以上内容为证券之星据 ...

Core Viewpoint - Shanghai Yueshen Health Group Co., Ltd. has announced a share repurchase plan, aiming to buy back a portion of its issued A-shares to reduce registered capital, with a total repurchase amount between RMB 6 million and RMB 10 million [2]. Group 1 - The company held board meetings on February 26, 2025, and March 25, 2025, where the share repurchase plan was approved [2]. - The repurchase price will not exceed RMB 5 per share, with an estimated repurchase quantity ranging from 1.2 million to 2 million shares, accounting for approximately 0.13% to 0.22% of the total share capital [2]. - The repurchase period will last up to 12 months from the date of the shareholders' meeting approval [2]. Group 2 - As of March 31, 2025, the company has not yet implemented the share repurchase [3]. - The company will continue to execute the repurchase plan based on market conditions and will fulfill its information disclosure obligations as required by relevant laws and regulations [3].

Core Viewpoint - The stock of Yueshen Health experienced a significant decline of 8.85% today, with a trading volume of 627 million yuan and a turnover rate of 13.98% [1] Trading Activity - The stock's trading amplitude was 7.22%, and it was listed on the Dragon and Tiger list due to a daily price deviation of -8.44% [1] - Institutional investors net sold 8.8298 million yuan, while the total net selling by brokerage seats amounted to 3.0168 million yuan [1] - The top five trading departments on the Dragon and Tiger list had a combined transaction volume of 137 million yuan, with buying transactions totaling 62.4422 million yuan and selling transactions totaling 74.2887 million yuan, resulting in a net selling of 11.8466 million yuan [1] Institutional Participation - Among the trading departments listed, three institutional special seats were involved, with a total buying amount of 14.3403 million yuan and a selling amount of 23.1701 million yuan, leading to a net selling of 8.8298 million yuan [1] - Over the past six months, the stock has appeared on the Dragon and Tiger list five times, with an average price drop of 6.06% the next day and an average increase of 2.09% over the following five days [1] Capital Flow - The stock saw a net outflow of 24.5448 million yuan in main funds today, with a significant outflow of 12.9336 million yuan from large orders and 11.6112 million yuan from big orders [1] - In the past five days, the main funds experienced a net inflow of 39.0173 million yuan [1]

Investment Rating - The industry investment rating is maintained as "Recommended" [1] Core Views - The real estate beta factor is more positive, suggesting a proactive layout in retail building materials [5] - Attention is drawn to the cement industry's bottom improvement, with price increases stabilizing profits during the off-season, indicating emerging bottom signals [7] - It is recommended to focus on high-dividend stocks for their allocation value [8] - The strategy for 2025 indicates a profit bottom and an impending supply-demand turning point [11] Market Performance - The report includes a section on market performance for the period from February 17 to February 21, 2025 [14] Price Changes - Cement prices showed fluctuations during the specified period, with detailed analysis provided [17] - The float glass and photovoltaic glass market experienced specific changes, particularly in the North China market, where prices were on a downward trend due to weak demand [26] - The domestic alkali-free roving yarn market saw a slight price increase, with the average price rising by 0.80% week-on-week and 22.11% year-on-year [33] Key Company Tracking and Industry News - Significant company announcements include shareholding changes and stock repurchase activities from various companies such as China Jushi and Wan Nian Qing [46][48] - Industry news highlights include the release of optimization policies for public housing funds and the impact of recent policy measures on the real estate market [50]

东 兴 晨 报 东兴晨报 P1 分析师推荐 【东兴机械】机械行业：政府工作报告从提振消费、未来产业、有效投资三 维度利好机械设备行业（20250306） 事件：3 月 5 日，十四届全国人大三次会议在京开幕。《政府工作报告》提 出实施提振消费专项行动；培育壮大新兴产业、未来产业；积极扩大有效投 资。对应到机械设备行业，建议关注消费场景、具身智能、工程机械三条主 线。 冰雪消费高景气或每年带来设备增量超 200 亿元。政府工作报告提到落实和 优化休假制度,释放文化、旅游、体育等消费潜力，其中冰雪消费旅游近年来 需求旺盛，相关设备投资将带来增量市场。考虑到高端和大型滑雪场建设需 要特定的地形和气候作为自然资源禀赋，未来增长空间有限。高端和大型客 群主要以旅游度假为目的，其客群到访具有较强的季节性，集中在节假日到 访。而室内和中小型滑雪场客群为初学者或体验型客户，在掌握一定滑雪技 能后，成为大型高端滑雪场稳定客源。随着国内人均收入的提升和国家政策 的扶持，预计未来各地室内和中小型滑雪场数量将持续增长。我国目前有 333 各地级行政区，假设未来 5 年内每个地级区建设 2 家滑冰场或滑雪场，假设 每个中小型滑雪场或滑 ...

Core Viewpoint - The article highlights the recent trend of foreign investment in China's industrial manufacturing sector, indicating a positive outlook for the recovery of Chinese manufacturing and a renewed focus of global capital on the Chinese market [1]. Group 1: Investment Activities - Singapore's Government Investment Corporation (GIC) has increased its stake in Huaming Equipment, holding 18.08 million shares, which is 2.02% of the total share capital [3]. - Barclays and Goldman Sachs have also increased their holdings in Yuexin Health, acquiring 2.25 million shares (0.24%) and 1.97 million shares (0.21%) respectively [5][6]. - Morgan Stanley has increased its stake in Weiman Sealing, holding 370,000 shares, which is 0.31% of the total share capital [8]. Group 2: Company Profiles - Huaming Equipment is the only domestic manufacturer with two complete industrial chain production bases for tap-changer products, holding over 80% of the domestic market share after acquiring its largest competitor in 2019 [3][4]. - Yuexin Health operates in health and wellness services, manufacturing and selling health-related building materials, and leasing investment properties, focusing on digital transformation in healthcare [5][6]. - Weiman Sealing specializes in hydraulic and pneumatic sealing products, with a focus on high-end materials and technology development, aiming for domestic market replacement in the sealing industry [8].

Core Viewpoint - The article highlights the recent trend of foreign investment in China's industrial manufacturing sector, indicating a renewed focus on investment opportunities as companies announce share buybacks and foreign institutions increase their holdings in potential stocks [1][2]. Group 1: Foreign Investment Activities - Several prominent foreign institutions have recently increased their stakes in potential stocks within the industrial manufacturing sector, signaling confidence in the recovery of China's manufacturing industry [2]. - The Singapore Government Investment Corporation (GIC) has increased its holdings in Huaming Equipment, while Barclays and Goldman Sachs have raised their stakes in Yueshin Health [2][5]. - Morgan Stanley has also increased its investment in Weiman Sealing, reflecting a broader trend of foreign capital re-engaging with the Chinese market [2][7]. Group 2: Company-Specific Insights - **Huaming Equipment**: GIC now holds 18.08 million shares, representing 2.02% of the total share capital. The company is recognized for its comprehensive production capabilities in transformer tap changers and has a significant market share in China [3][4]. - **Yueshin Health**: Barclays and Goldman Sachs have increased their holdings by 2.25 million shares combined, focusing on health and wellness services, as well as smart healthcare solutions [5][6]. - **Weiman Sealing**: Morgan Stanley holds 370,000 shares, accounting for 0.31% of the total share capital. The company specializes in hydraulic and pneumatic sealing products and is working on high-end material development to enhance its market position [8].

Group 1 - The government work report sets a GDP growth target of around 5% for 2025, with a fiscal deficit rate of 4% and a CPI target of 2%, aligning with market expectations [9][36] - The report emphasizes the importance of expanding domestic demand and boosting consumption as key drivers for economic growth, reflecting a strong commitment to stimulate the consumer market [27][28] - The focus on new technologies and emerging industries, particularly in artificial intelligence and digital economy, is highlighted as a priority for future development, indicating a significant investment opportunity in the tech sector [2][6] Group 2 - The report outlines ten measures to boost consumption, including enhancing service consumption and improving the quality of consumer goods, which is expected to benefit companies in the consumer sector [27][28] - The emphasis on high-quality development and the need to combat "involution" in the transportation industry suggests a shift towards more sustainable and efficient practices, which could impact logistics and transport companies positively [21][23] - The report mentions the importance of the low-altitude economy and new emerging industries, indicating potential growth areas for companies involved in logistics technology and smart transportation solutions [24][25] Group 3 - The government plans to issue 1.3 trillion yuan in special bonds to support consumption upgrades, which is expected to significantly stimulate demand in sectors like home improvement and consumer electronics [32][34] - The report indicates a strong focus on the integration of advanced manufacturing and modern service industries, suggesting opportunities for companies that can adapt to this evolving landscape [10][22] - The commitment to maintaining a stable monetary policy environment, with potential for interest rate cuts, is likely to create favorable conditions for investment in various sectors, particularly real estate and consumer goods [37][39]

证券代码：002162 证券简称：悦心健康 公告编号：2024-050 上海悦心健康集团股份有限公司 关于2024年半年度计提资产减值准备的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 上海悦心健康集团股份有限公司（以下简称"公司"）根据《企业会计准则》、 《深圳证券交易所股票上市规则》及公司会计政策的相关规定，为更加真实、准确地 反映公司截止2024年6月30日的资产价值、财务状况和经营情况，对2024年6月30日合 并会计报表范围内的各类资产进行了全面清查、分析和评估，基于谨慎性原则，对可 能发生资产减值损失的相关资产计提减值准备，具体情况如下： 一、本次计提资产减值准备情况概述 二、本次计提资产减值准备的合理性说明 依据《企业会计准则》和公司相关会计政策规定，公司 2024 年半年度计提应收 账款、存货减值准备共计 6,072,078.46 元，转回其他应收款减值准备 12,507,069.89 元，是根据相关资产的实际情况并经资产减值测试后基于谨慎性原则而作出的，计提 资产减值准备依据充分，且公允的反映了公司资产状况、资产价值及经营成果，使公 司的会 ...

近日，公司完成了本次注册资本变更的工商登记手续和《公司章程》的备案手续， 取得了上海市市场监督管理局换发的《营业执照》。本次工商登记变更事项为公司注 册资本由人民币 92,650 万元变更为人民币 92,000 万元，其他工商登记事项未发生 变更。 特此公告。 上海悦心健康集团股份有限公司 董事会 证券代码：002162 证券简称：悦心健康 公告编号：2024-048 上海悦心健康集团股份有限公司 关于完成注册资本工商变更登记的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，不存在虚假记载、 误导性陈述或者重大遗漏。 上海悦心健康集团股份有限公司（以下简称"公司"）分别于 2024 年 5 月 21 日、2024 年 6 月 7 日召开了第八届董事会第八次会议、2024 年第一次临时股东大会， 审议通过了《关于变更回购股份用途并注销的议案》、《关于减少注册资本暨修订< 公司章程>的议案》，同意将公司回购专用证券账户中 650 万股股份的用途由"用于 股权激励计划或员工持股计划"变更为"用于注销并减少公司注册资本"，同时对《公 司章程》相应条款进行修订，并授权公司管理层办理工商变更登记等相关手续。 ...